Ascendis Pharma A/s

This phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…

This study tests a weekly injection called navepegritide in 24 teenagers (ages 12-18) with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over one year compared to a placebo. The treatment aims to manage the condition by im…

This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth over 52 weeks. About 72 babies will take part, with some receiving the drug and others a pla…

This study looks at how much of the drug palopegteriparatide (YORVIPATH) gets into breast milk. It involves 10 women with hypoparathyroidism who are already taking the drug and breastfeeding. Researchers will collect milk samples to measure drug levels, helping understand safety …

This registry study is collecting data from 50 women aged 15–50 who took YORVIPATH (palopegteriparatide) for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will monitor pregnancy complications, birth outcomes, and infant health through the fir…